- F&P Healthcare projects 2025 net income to be between NZ$310 million and NZ$360 million.
- Analysts estimate the net income for 2025 to be NZ$333 million.
- The company expects operating revenue to range from NZ$1.9 billion to NZ$2 billion in 2025.
- The estimated operating revenue for 2025 is NZ$1.95 billion.
- For the current year, F&P Healthcare reported a net income of NZ$132.6 million, below the estimated NZ$259.6 million.
- The final dividend per share for the year is 23.5 NZ cents.
- Operating revenue for the year reached NZ$1.74 billion, slightly above the estimate of NZ$1.73 billion.
- Analyst recommendations include: 2 buys, 10 holds, and 4 sells.
A look at Fisher & Paykel Healthcare Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have provided Smart Scores for Fisher & Paykel Healthcare Corp, indicating a mostly positive long-term outlook for the company. With above-average scores in Growth, Resilience, and Momentum, Fisher & Paykel Healthcare Corp is positioned well for future expansion and market performance. The company’s strong momentum score suggests a positive trend in its stock performance, indicating potential for continued growth.
Fisher & Paykel Healthcare Corp‘s focus on designing, manufacturing, and marketing products for respiratory care and sleep apnea treatment, including patient warming and neonatal care products, highlights its commitment to improving healthcare outcomes. These efforts align with its solid scores in Resilience and Growth, indicating a promising future for the company’s market position and overall performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
